Tectonic Therapeutic, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Tectonic Therapeutic, a clinical-stage biotechnology company, reported its 2025 annual financial results and provided updates on its lead product candidates, TX45 and TX2100, including ongoing clinical trials and future milestones.
NASDAQ
Tectonic Therapeutic, a clinical-stage biotechnology company, announces its full year 2024 financial results and provides an update on its clinical development programs, including TX45 for pulmonary hypertension and TX2100 for hereditary hemorrhagic telangiectasia.
NASDAQ
10-K: AVROBIO Halts Development, Explores Strategic Alternatives Amidst Merger with Tectonic Therapeutics
AVROBIO has ceased development of its gene therapy programs and is pursuing strategic options, including a merger with Tectonic Therapeutics, to maximize shareholder value.